What is Schrodinger's drug discovery — total backlog?

Schrodinger (SDGR) reported drug discovery — total backlog of $17.21M in Q1 2026.

What does drug discovery — total backlog mean?

This metric represents the total value of contracted revenue from drug discovery collaborations that has not yet been recognized as income. It serves as a key indicator of future revenue visibility and the strength of the company's long-term partnership pipeline in the pharmaceutical sector.

Schrodinger SDGR Drug discovery — Total backlog

Other product segments

Software products and services

$31.63M—

Similar metrics at other companies

ZYMEOther drug supply — Research and development collaborations

$117K-94.6%

ZYMEDrug supply for ongoing studies — Research and development collaborations

$345K-88.3%

ROIVOther development and discovery programs — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$13.43M-3.9%

PODDDrug Delivery — Total Revenue

$3.3M-77.9%

ZYMERecognition of deferred revenue — Research and development collaborations (note 11)

$0—

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

Other financials

Income statement

See full

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

See full

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

See full

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

See full

Market cap$1.15B-23.7%

Enterprise value$984.71M-23.1%

P/S4.5×-2.0×

Profitability

See full

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

See full

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept sdgr:RevenueRemainingPerformanceObligationBacklog.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's drug discovery — total backlog.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Schrodinger's drug discovery — total backlog?: Schrodinger (SDGR) reported drug discovery — total backlog of $17.21M in Q1 2026.
What does drug discovery — total backlog mean?: This metric represents the total value of contracted revenue from drug discovery collaborations that has not yet been recognized as income. It serves as a key indicator of future revenue visibility and the strength of the company's long-term partnership pipeline in the pharmaceutical sector.